Cystic Fibrosis APIs: Sigachi Develops Three-Drug Therapy with Vanzacaftor Tezacaftor Deutivacaftor

Sigachi Industries Limited has developed a new three-drug Active Pharmaceutical Ingredient combination for cystic fibrosis. The mix includes Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks a key stage in Sigachi Industries’ research pipeline and supports its focus on complex, high-value specialty APIs in chronic and rare disease therapies.

The move aligns with global demand for next-generation cystic fibrosis treatments. These therapies often require lifelong use and show strong price resilience. Against this backdrop, Sigachi Industries is positioning its cystic fibrosis APIs portfolio as a long-duration growth opportunity within a specialised, structurally steady therapeutic segment.

The worldwide cystic fibrosis drugs market is projected at about USD 10 billion. Demand is supported by rising use of modulator therapies, extended treatment durations, and stable pricing trends. By entering cystic fibrosis APIs, Sigachi Industries gains access to a global market with predictable long-term usage and technical differentiation.

Advanced process chemistry sits at the core of these Sigachi Industries cystic fibrosis APIs. The portfolio involves multi-step synthesis and specialised reactions that raise technological complexity. Such features increase barriers to entry, reduce competitive intensity, and deepen Sigachi Industries’ competencies in sophisticated API manufacturing for demanding therapeutic segments.

Vanzacaftor, one of the key cystic fibrosis APIs in the combination, is covered by innovator patent protection until 2039. This extended patent life supports visibility on potential licensing avenues, collaboration-led supply agreements, and revenue stability for Sigachi Industries across the cystic fibrosis therapy space over the coming decade and beyond.

Guided by internal market studies and strategic review, Sigachi Industries is exploring alliances with formulation developers. These partnerships would cover research, scale-up, and future commercial supply of the cystic fibrosis APIs. Subject to successful tie-ups and market traction, the company estimates annual revenue potential above Rs 250 crore from Q4 FY2026-2027.

Lijo Chacko, Deputy Group CEO, Sigachi Industries Limited, said, "This milestone reflects Sigachi's focused strategy of building depth in complex and differentiated APIs with long-term growth visibility. Our continued investments in R&D and partnerships are aimed at strengthening our position in high-entry-barrier specialty segments and creating sustainable value for stakeholders."

Sigachi Industries cystic fibrosis APIs business profile

While adding new high-value projects such as cystic fibrosis APIs, Sigachi Industries continues to strengthen its existing operations. The company works across active pharmaceutical ingredients, intermediates, excipients, vitamin-mineral premixes, and operations and management (O&M) services. Production takes place at multi-location facilities in Telangana, Gujarat, and Karnataka, covering a diversified product range.

Sigachi Industries’ activities and manufacturing footprint can be summarised as follows:

Business area	Key activities
APIs and intermediates	Development and production of complex and specialty molecules, including cystic fibrosis APIs
Excipients and blends	Manufacture of excipients and vitamin-mineral blends for pharmaceutical and nutraceutical use
O&M services	Operations and management support for pharmaceutical manufacturing facilities
Manufacturing locations	Five facilities across Telangana, Gujarat, and Karnataka

With 36 years in the pharmaceutical sector, Sigachi Industries supplies clients in more than 65 countries. The company remains focused on its core lines while adding innovative, high-value projects. The cystic fibrosis APIs initiative fits this strategy by combining technical complexity, patent-backed visibility, and long-term market demand prospects.